Target intelligence / Profile preview

Dendritic cell activation via damage-associated molecular patterns

Molecular classification
Pattern recognition receptors (PRRs), Toll-like receptors (TLRs), NOD-like receptors (NLRs), Receptor (general class for TLRs/NLRs)
01

Overview

Activation of dendritic cells via damage-associated molecular patterns (DAMPs) describes the process by which endogenous molecules released from stressed or damaged cells (such as HMGB1, ATP, and uric acid) are recognized by pattern recognition receptors (e.g., Toll-like receptors, NOD-like receptors) on dendritic cells. This interaction drives dendritic cell maturation, enhances their antigen-presenting capacity, and promotes pro-inflammatory cytokine production, playing a crucial role in bridging innate and adaptive immunity. This process is fundamental in host defense, sterile inflammation, autoimmunity, transplant rejection, and antitumor responses. Overall, "Dendritic cell activation via damage-associated molecular patterns" is a pathway/process, not a discrete molecular target, and is best described in the context of the key receptors involved (such as TLR4 or NLRP3) and the DAMP ligands they recognize.

Other names
DAMP-induced dendritic cell activationDC activation by danger signalsdendritic cell maturation by DAMPs
02

Mechanism of action

Drugs targeting TLRs or downstream cytokines may blunt dendritic cell activation/maturation in response to DAMPs. Some experimental therapies block specific DAMPs (e.g., HMGB1 antagonists) or PRRs.

03

Biological functions

Immune responseSignal transductionInflammationAntigen presentationBridge between innate and adaptive immunity
04

Disease associations

InflammationAutoimmunityTumor immunityTransplant rejectionChronic inflammatory diseasesInfectionOther (e.g., ischemia reperfusion injury)
05

Safety considerations

Immunosuppression (if targeting the pathway therapeutically, risk of infection or reduced antitumor immunity)Exacerbation of autoimmunity or chronic inflammation (if pathway is overactive)
06

Interacting drugs

TLR antagonists

2 more in the full profile.

07

Biomarkers

Elevated DAMPs (such as HMGB1, HSPs)Increased DC maturation markers (CD80, CD86, MHC-II)Inflammatory cytokines (IL-1β, TNF-α, IL-6)

Beyond the preview

Go deeper on Dendritic cell activation via damage-associated molecular patterns.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dendritic cell activation via damage-associated molecular patterns.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call